Drugs / AGEN1777
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05025085 | Oct 2021 → Jul 2023 | — | Agenus Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | Agenus Inc. | Results Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 agenusbio.com ↗
In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to conventional TIGIT antibodies. |
| 2021-07-06 | Agenus Inc. | Regulatory Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 agenusbio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | Agenus Inc. | Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 agenusbio.com ↗ |
| 2021-07-06 | Agenus Inc. | Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 agenusbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGEN1777 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05025085 ↗ |
| Route | Intravenous | “administered by Intravenous (IV) infusion” NCT05025085 ↗ |